SRR614814
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.417
- PANCREAS_BETA_CELLS+0.368
- KRAS_SIGNALING_DN+0.322
- UV_RESPONSE_DN+0.312
- HEDGEHOG_SIGNALING+0.254
- KRAS_SIGNALING_UP+0.211
- APICAL_SURFACE+0.190
- SPERMATOGENESIS+0.152
- ESTROGEN_RESPONSE_EARLY+0.150
- ESTROGEN_RESPONSE_LATE+0.145
Top 10 suppressed
- MYC_TARGETS_V2-0.589
- MYC_TARGETS_V1-0.541
- DNA_REPAIR-0.467
- UNFOLDED_PROTEIN_RESPONSE-0.464
- E2F_TARGETS-0.456
- G2M_CHECKPOINT-0.428
- CHOLESTEROL_HOMEOSTASIS-0.407
- MTORC1_SIGNALING-0.407
- PROTEIN_SECRETION-0.372
- P53_PATHWAY-0.294
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1407134 | GTEX | — | 0.940 |
| 2 | BS_QF5VVZX5 | Ganglioglioma | — | 0.928 |
| 3 | SRR599448 | GTEX | — | 0.924 |
| 4 | SRR1472323 | GTEX | — | 0.916 |
| 5 | SRR1339651 | GTEX | — | 0.913 |
| 6 | SRR656552 | GTEX | — | 0.912 |
| 7 | SRR614479 | GTEX | — | 0.912 |
| 8 | SRR1418127 | GTEX | — | 0.912 |
| 9 | SRR1375976 | GTEX | — | 0.911 |
| 10 | BS_NFRXNAFE | ganglioneuroblastoma | — | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.417 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.368 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.322 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.312 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.254 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.211 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.152 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.145 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.138 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.115 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.104 | Inavolisib | — uncovered |
| COAGULATION | 0.097 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.086 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.071 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.034 | Temsirolimus | — uncovered |